| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Cancer Biology, Immunology, Cytokines |
Medical College of Pennsylvania and Hahnemann University, Department of Pathology and Laboratory Medicine, Philadelphia, Pennsylvania 19102-1192 [M. E. S., F. U. G., K. F., M. W.], and NIH-National Cancer Institute, Frederick, Maryland 21702 [J. R.]
 |
ABSTRACT |
|---|
 Top ABSTRACT INTRODUCTIONMATERIALS AND METHODSRESULTSDISCUSSIONREFERENCES |
|---|
|
INTRODUCTION |
|---|
|
TopABSTRACTINTRODUCTIONMATERIALS AND METHODSRESULTSDISCUSSIONREFERENCES |
|---|
, IL-6, and matrix metalloproteinase 9 in activated macrophages that normally infiltrated the tumor tissues. The authors suggested that the production of IL-10 by tumor cells might inhibit macrophage-derived angiogenic factors to block tumor growth and metastasis indirectly (1)
. Alternatively, IL-10 might sensitize tumor cells to natural killer cells, which blocked metastasis as shown in a murine model of breast cancer (2)
. In similar studies, Richter et al. (3)
reported that IL-10 blocked tumor growth apparently by blocking angiogenesis and macrophage penetration of the tumor tissue. Kundu et al. (2)
also found with studies of IL-10-transfected murine mammary tumor cell lines that tumor growth was completely inhibited and metastasis was reduced by 
90% in syngeneic BALB/ccByJ mice. The effect appeared to be independent of T-cell activity but was dependent on natural killer cell function. These observations suggest that the production of IL-10 by tumor cells might inhibit macrophage-derived angiogenic factors to block tumor growth, angiogenesis, and metastasis indirectly (2)
. In apparent contrast to these findings, Sato et al. (4)
found that IL-10 expression was characteristic of human metastatic melanomas, implying that IL-10 might down-regulate the antitumor activities of monocytes and macrophages, blocking production of antitumor effector molecules (5)
, to thereby enable metastasis (4)
. Additional studies are required to resolve the role of IL-10 in tumor growth and metastasis as a function of the tissue of origin, the type of cancer, or whether differences exist between tumors in rodents and humans. The role of other cytokines in the process will also be critical. Recently, several studies have reported that EL4 tumor cells secreted TGF-ß and IL-10 in vitro (6 , 7) and in vivo. Studies in C57BL/6 mice indicated that EL4 tumor growth avoided macrophage-immune surveillance by secreting TGF-ß to regulate macrophage secretion of antitumor components (8) . The amounts of tumor-secreted TGF-ß increased with tumor growth and appeared to induce IL-10 production by the macrophages, which in turn suppressed the antitumor activities of the macrophages (8) . The studies failed to assess whether IL-10 also influenced TGF-ß production by the tumor cells or whether IL-10 expression modulated tumor growth and metastasis.
Differences among organ sites of the tumor origin might be a factor influencing cytokine activity. For example, Greene et al. (9) have elegantly shown that the elevated expression of epidermal growth factor receptor, basic fibroblast growth factor, IL-8, MMP-2, MMP-9, and multidrug resistance-1 correlated with the increased metastatic potential of human prostate PC-3M cancer cells implanted into the prostate of nude mice (9) . Their data demonstrated that the organ site of tumor cell implantation strongly modulated gene expression and metastasis of the tumor cells.
Utilizing a similar approach, in this report we have examined whether permanent IL-10 and TGF-ß1 gene transfection of four different HPCA-10a, 10b, 10c, and 10d-HPV-18 lines [i.e., derived from microdissections of Gleason score 10 glands and immortalized with HPV-18 infection (10) ] influenced growth in vitro plus tumor cell growth, metastasis, and mouse survival rates after orthotopic implantation of the cells in SCID mice. In addition, the influence of these genes on the expression of TIMP-1, MMP-2, and factor VIII levels (i.e., the degree of tumor angiogenesis) has been measured in relation to tumor metastasis and mouse survival. The results showed that: (a) IL-10 up-regulated TIMP-1 and down-regulated MMP-2 to block angiogenesis, growth, and metastasis of tumors; and (b) TGF-ß1 up-regulated MMP-2 to stimulate tumor growth, angiogenesis, and metastasis. Increased mouse survival was correlated with IL-10 activity and inversely correlated with TGF-ß1 expression, indicating that IL-10 might be of therapeutic value in treating patients with cancer who have a high probability of metastasis.
|
MATERIALS AND METHODS |
|---|
|
TopABSTRACTINTRODUCTIONMATERIALS AND METHODSRESULTSDISCUSSIONREFERENCES |
|---|
IL-10 and TGF-ß1 Gene Transfections.
Total cytoplasmic RNA was isolated from 107 human prostate PC-3 cells treated with 10 µg/ml ConA. RNA was reverse transcribed into cDNA using oligo dT primer as described by others (11)
, then amplified 40 cycles using two oligonucleotide primers derived from a published IL-10 sequence (12)
, including 5'-AATGGAGCTCGCTCTAGAATGCACAGCTCAGCACTG-3' and 5'-AATGGATATCGCGAATTCTTTCTCAAGGGGCTGGGT-3', incorporating an SstI and an EcoRV site, respectively (underlined), and from a TGF-ß1 sequence (13)
, including: TGF-ß8, 5'-GAGGTCACCCGCGTGCTAATG-3'; and TGF-ß9, 5'-GGCCAGGACCTTGCTGTACTG-3', incorporating an SstI and an EcoRV site, respectively (underlined). PCR was carried out for 20 s at 94°C, 20 s at 60°C, and 20 s at 72°C for 40 cycles, followed by a 10-min extension at 72°C. The PCR product was then cloned into a Bluescript vector (Stratagene, La Jolla, CA), and several independent clones were sequenced to confirm that the IL-10 and the TGF-ß1 gene had been cloned. One of each of the cDNAs was subcloned into a expression vector pCEP4 (Invitrogen, San Diego, CA). HPCA-10a, 10b, 10c, and 10d cells were transfected with the pCEP4 vector alone (HPCA-10a, 10b, 10c, and 10d-HPV-18 Mock) or with either the pCEP4-TGF-ß1, the pCEP4-IL-10 vector independently, or with both simultaneously (i.e., HPCA-10a-IL-10 and TGF-ß1 Mock) using the Lipofectamine method (Oncogene Science, Bedford, MA). After transfection, hygromycin (400 µg/ml)-resistant cells were selected over a 2-month period, the cells were pooled, and single cell clones were generated by limited dilution in 96-well dishes. At least two different clones were generated and characterized for each vector. The clones were amplified in five passages, and cells were frozen in liquid nitrogen for future studies. Cells were revived and used at a final passage <5 in all experiments. ELISAs (see methods below) with IL-10 and TGF-ß1 antibodies (Santa Cruz Biotechnology, Santa Cruz, CA) confirmed that each of the clones still produced IL-10 and TGF-ß1 (>10 pg/ml).
Anchorage-dependent Cell Proliferation Assay.
The biological activity of IL-10 and TGF-ß1 was determined using the colorimetric MTT (Sigma Chemical Co., St. Louis, MO) dye-reduction assay (14
, 15)
. In brief, the HPCA-10-HPV-18 cells (1 x 104 cells/well in 200 µl of medium containing 2% FCS) were exposed to 30 ng/ml IL-10 or 10 ng/ml TGF-ß1 for 72 h in a 96-microtiter well. Ten µl of 5 mg/ml MTT was added and incubated for 4 h, the cells were then detergent-lysed in absolute ethanol and the plates were read for absorbance at 570 nm. Cell viability in the experiments was estimated by trypan blue exclusion assays as >95%.
Immunohistochemistry.
Tissues were processed for antibody labeling according to methods described previously (16)
using primary IL-10 (Schering-Plough, Kennilworth, NJ) and TGF-ß1 (Santa Cruz Biotechnology) antibodies at a dilution of 1:500 and secondary peroxidase-anti-peroxidase antibodies (Sigma) at a dilution of 1:400. At least three sections were labeled from each tissue, and one section was labeled with secondary antibody only as a control. One additional section was stained with H&E for identification of the cells.
ELISAs.
ELISAs were carried out as described previously (16)
using well-characterized IL-10 (courtesy of Dr. N. Sawant, Schering-Plough, Kennilworth, NJ); TGF-ß1 (Santa Cruz Biotechnology), and TIMP-1 and MMP-2 monoclonal antibodies (16)
. Standard curves were developed previously for each of these antibodies (16)
to enable measurements of the antigen levels in crude protein extracts. Factor VIII antibodies were from Sigma. ELISAs (A, 490 nm) were performed using aliquots of crude protein extracts (16)
to coat the EIA-plates (Dynatech, Chantilly, VA). After blocking with 5% bovine serum albumin, excess primary antibody (100 µl/well at 1 µg/ml) was added and incubated at 37°C for 2 h. A Vector Elite kit (Vector, Burlingame, CA) was used to detect the bound antibody with goat or rabbit anti-mouse secondary antibody and o-phenylenediamine as peroxidase substrate. Amounts of antigen in crude tumor extracts were determined from the standard curves.
The absorbance readings (A, 490 nm) were obtained for three protein concentrations of the crude protein extract from cells or tumor tissue (0.25, 0.50, and 1.0 mg of protein), and the actual amounts of IL-10, TGF-ß1, TIMP-1, and MMP-2 antigen produced by each cell line were determined from a standard curve comparing absorbance readings to known amounts of purified IL-10 (Schering-Plough) or TGF-ß1 (Sigma), TIMP-1 and MMP-2 as described previously (16) . The readings were then normalized for 1.0 mg of protein. Protein levels were measured according to the method of Bradford et al. (17) .
Mice.
Pathogen-free male SCID/SCID mice were purchased from Taconic Laboratories (Albany, NY) and housed in barrier cages in a barrier facility. Mice were fed a standard laboratory chow ad libitum and were used at 8–10 weeks of age. Orthotopic injection was carried out according to methods described by Greene et al. (9)
. After experimental treatment, the mice were sutured with staples and watched for 3 days to ensure recovery.
Statistical Analysis.
Differences in the number of colonies of the lung, liver, and peritoneum were analyzed using the Mann-Whitney U test. Statistical significance was determined by a two-way analysis of variance or by the two-tailed Student’s t test (Minitab, Statistical Software 8.2), and results are expressed as the mean ± 1 SD of replicate determinations.
|
RESULTS |
|---|
|
TopABSTRACTINTRODUCTIONMATERIALS AND METHODSRESULTSDISCUSSIONREFERENCES |
|---|
180, 250, and 300% in response to either IL-10, TGF-ß1, and IL-10 plus TGF-ß1, respectively. Moreover, trypan blue exclusion assays showed that cell viability was >95% in the absence or presence of increased amounts of either cytokine.
Colony-forming Assays in Soft Agar
Colony-forming assays in soft agar further revealed that the different HPCA-10a–d lines grew under anchorage-independent conditions in the presence of 2% FCS (and vehicle) for 72 h (Table 1)
. The degree of colony formation by HPCA-10a cells were supported IL-10 and TGF-ß1 (i.e., by 30 ng/ml IL-10 and by 1 ng/ml TGF-ß1) in the presence of 2% FCS (Table 1)
. HPCA-10a clones independently transfected with TGF-ß1 and IL-10 genes (or cotransfected with both genes) tended to exhibit a colony-forming ability comparable with the nontransfected HPCA-10a cells. Exogenously supplied IL-10 (1 and 10 ng/ml) had little noticeable effect, but 10 ng/ml TGF-ß1 tended to stimulate colony formation by a significant degree (Table 1)
. Similar results were observed with HPCA-10 c–d clones (data not shown).
|
, studies with nontransfected (panel 1) or mock-transfected HPCA-10a clones (panels 2 and 6) revealed that the average size of the tumors increased from <1 mm3 at 8 weeks (column a, panels 1, 2, and 6) to 1.5 mm3 at 12 weeks (column b, panels 1, 2, and 6) and 2.7 mm3 at 16 weeks (column c, panels 1, 2, and 6). Similarly, the tumor volume of the HPCA-10a-TGF-ß1 (panel 4)-transfected cells increased from 0.5, 1.8, and 3 mm3 by 8, 12, and 16 weeks, respectively. Although the data were not statistically different from nontransfected cells (P > 0.1), TGF-ß1 appeared to promote growth. In contrast, the tumor volume of HPCA-10a-IL-10 (panel 3) and HPCA-IL-10 and TGF-ß1 (panel 5)-transfected cells was significantly reduced and ranged from 0.2 to 0.5 mm3 after 8, 12, and 16 weeks (columns a, b, and c; panels 3 and 5), indicating IL-10 expression retarded tumor growth in vivo (P < 0.001). Other experiments showed that after mixing of equal numbers of cells from the HPCA-10a-IL-10 and HPCA-10a-TGF-ß1-transfected clones (and injected at a final concentration of 1 x 107 cells in 0.05 ml), the tumor volume was also reduced to <0.5, 1, and 1.5 mm3 by 8, 12, and 16 weeks, respectively (P < 0.05; data not shown). Presumably, IL-10 produced by the HPCA-10a-IL-10 cells retarded growth of the HPCA-10a-TGF-ß1 cells. Similar results were observed in comparable studies with the HPCA-10b, 10c, and 10d clones (data not shown).
|
). The data showed that HPCA-10a parent; HPCA-10a-IL-10 Mock; HPCA-10a-TGF-ß1 Mock, HPCA-10a-IL-10 and TGF-ß1; and HPCA-10a-IL-10 and TGF-ß1 Mock cells metastasized at a very low frequency after 16 weeks. The majority of the metastases were observed in the peritoneum (in 5 of 20 to 6 of 20 mice) as compared with the lung (1 of 20 mice), liver (2 of 20 to 3 of 20 mice), brain (0 of 20 mice), or bone marrow (1 of 20 mice). The number of tumor nodules/organ site was also small (i.e., <5/organ site). Likewise, the HPCA-10a-IL-10-transfected clones produced metastases to different organ sites in a small number of mice (ranging from 1 of 20 to 3 of 20 mice) with <2 nodules/organ site. In contrast, the HPCA-10a-TGF-ß1 clones exhibited a significantly elevated frequency of metastasis to different organ sites including the lung (5 of 20 mice; P < 0.001), liver (7/20 mice; P < 0.001), and peritoneum (14 of 20 mice, P < 0.001) compared with controls. The numbers of tumor foci per organ site of metastasis varied depending on the organ size but were significantly elevated in the TGF-ß1-transfected clones (ranging from 15 to 30 nodules/organ site in the lung, liver, and peritoneum; P < 0.001). Interestingly, the degree of metastasis to the brain and bone marrow (i.e., 1 of 20 to 2 of 20 mice) was comparable with controls. Similar results were observed with the three other HPCA-10b, 10c, and 10d clones transfected with HPCA-10a-IL-10 and TGF-ß1.
|
or TGF-ß1-transfected cells (Fig. 2B)
with that observed in the IL-10 transfected cells (Fig. 2, C and D)
clearly indicated that IL-10 expression was elevated in the latter tumors. Likewise, TGF-ß1 levels were moderate in nontransfected HPCA-10a (Fig. 3A)
and in HPCA-10a-IL-10 (Fig. 3C)
and HPCA-10a-IL-10 and TGF-ß1 cotransfected cells (Fig. 3D)
but elevated in the HPCA-10a-TGF-ß1-transfected tumor cells (Fig. 2B)
. The TIMP-1 levels correlated with IL-10 expression in the HPCA-10a-IL-10-transfected cells (compare Fig. 4, A
and 4B
, with C and D
). In contrast, MMP-2 was highly expressed in nontransfected HPCA-10a and HPCA-10a-TGF-ß1-transfected cells (Fig. 5, A and B)
, only faintly expressed in the HPCA-10a-IL-10-transfected cells (Fig. 5C)
, and moderately expressed in the HPCA-10a-IL-10 and TGF-ß1 cotransfected cells (Fig. 5D)
. Similar results were observed with the different HPCA-10b, 10c, and 10d clones described in Tables 1
and 2
(data not shown).
|
ELISA measurements confirmed that IL-10-transfected and IL-10 plus TGF-ß1 cotransfected HPCA-10a tumor cells expressed increased levels of IL-10 after implantation orthotopically in SCID mice for 8, 12, or 16 weeks (i.e., 40–90 ng/mg protein, Fig. 6
, panels 1–3, columns c and e, respectively). Controls showed that relatively low levels of IL-10 were expressed by the HPCA-10a parent cells (Fig. 6
, panels 1–3, column a), HPCA-10 IL-10 Mock (Fig. 6
, panels 1–3, column b), and HPCA-10a-IL-10 and TGF-ß1 Mock (Fig. 6
, panels 1–3, column f). Likewise, TGF-ß1 and IL-10 plus TGF-ß1 cotransfected tumor cells expressed significantly elevated levels of TGF-ß1 (i.e., 35–90 ng/mg protein, Fig. 7
, panels 1–3, columns d and e) after orthotopic implantation for 8, 12, and 16 weeks. Controls showed that relatively low levels of TGF-ß1 were expressed by the HPCA-10a parent cells (Fig. 7
, panels 1–3, column a), HPCA-10a-IL-10 Mock (Fig. 7
, panels 1–3, column b), HPCA-10a-IL-10 (Fig. 7
, panels 1–3, column c), and HPCA-10a-IL-10 and TGF-ß1 Mock (Fig. 7
, panels 1–3, column f). Measurements of mouse prostate tissue showed that neither cytokine was expressed to a significant degree by nontumor tissue (i.e., the levels were <2 ng/mg protein).
|
|
10 ng/mg in crude protein extracts from the tumor tissue derived from the three different HPCA-10a, 10b, 10c, and 10d tumor clones at 16 weeks. The TGF-ß1 levels ranged from 10 to 30 ng/mg protein in these tumors. Likewise, tumor tissue from four different IL-10-transfected HPCA-10a, 10b, 10c, and 10d clones ranged from 70 to 120 ng/mg in crude protein in 16-week tumors. The TGF-ß1-transfected HPCA-10a, 10b, 10c, and 10d clones each expressed TGF-ß1 at levels ranging from 60–90 ng/mg protein after 16 weeks, confirming that the data presented in Figs. 6
and 7
were not artifactual.
TIMP-1 and MMP-2.
The relative levels of TIMP-1 and MMP-2 expressed by different HPCA-10a clones were measured after 8, 12, and 16 weeks (Figs. 8
and 9
, columns a, b, and c, respectively). Fig. 8
showed that the TIMP-1 levels ranged from 10 to 30 ng/mg protein in tumors formed from HPCA-10a (panel 1); HPCA-10a-IL-10 Mock (panel 2); HPCA-10a-TGF-ß1 (panel 4); and HPCA-10a-IL-10 and TGF-ß1 Mock (panel 6) lines after 8, 12, and 16 weeks (columns a, b, and c, respectively). In contrast, the TIMP-1 levels were significantly elevated in tumors from HPCA-10a-IL-10 (panel 3); and HPCA-10a-IL-10 and TGF-ß1 (panel 5)-transfected tumors after 8, 12, and 16 weeks (columns a, b, and c, respectively). Fig. 9
showed that the MMP-2 levels ranged from 30 to 70 ng/mg protein in tumors formed from HPCA-10a (panel 1); HPCA-10a-IL-10 Mock (panel 2); and HPCA-10a-IL-10 and TGF-ß1 Mock (panel 6)-transfected lines after 8, 12, and 16 weeks (columns a, b, and c, respectively). The MMP-2 levels were significantly elevated in tumors from HPCA-10a-TGF-ß1-transfected lines (panel 4). In contrast, the tumors from HPCA-10a-IL-10 (panel 3) and HPCA-10a-IL-10 and TGF-ß1 (panel 5) transfected tumors failed to express significant amounts of MMP-2 after 8, 12, and 16 weeks (columns a, b, and c, respectively).
|
|
, panels 1–6, column a). However, in nontransfected HPCA-10a cells (panel 1) HPCA-10a-IL-10 Mock (panel 2), HPCA-10a-TGF-ß1 (panel 4), and HPCA-10a-IL-10 and TGF-ß1 Mock (panel 6)-transfected tumors, the factor VIII levels ranged from 20 to 30 ng/mg; and from 30 to 48 ng/mg protein in the 12- and 16-week tumors, respectively (Fig. 10
, columns b and c). In comparison, the HPCA-10a-IL-10-transfected (panel 3) and HPCA-10a-IL-10 and TGF-ß1 cotransfected (panel 5) cell tumors exhibited factor VIII levels of 1 ng/mg at 8, 12, and 16 weeks (Fig. 10
, columns a, b, and c), indicating that little or no tumor-associated angiogenesis had occurred.
|
showed that in metastases to the peritoneum, the levels of TGF-ß1 ranged from 20 to 25 ng/mg protein in the HPCA-10a-IL-10 and TGF-ß1 Mock (panel 1); HPCA-10a-IL-10 (panel 3); and HPCA-10a-IL-10 and TGF-ß1 (panel 4)-transfected clones (Fig. 11
, column a). TGF-ß1 levels were 60 ng/mg protein in metastases to the peritoneum by the HPCA-10a-TGF-ß1-transfected clones (panel 2, column a). However, IL-10 levels were uniformly low (<2 ng/mg protein) in all peritoneum metastases from the different clones (Fig. 11
, columns b). The TIMP-1 levels were also uniformly low (10 ng/mg protein, Fig. 11
, columns c), but the MMP-2 levels were uniformly high (40 to 60 ng/mg protein, Fig. 11
, columns d) in peritoneum metastases from all four HPCA-10a clones.
|
Attempts to measure the levels of TIMP-2 and MMP-9 by ELISA yielded consistently low levels (<5 to 10 ng/mg protein) in either the primary tumors or the metastases from any of the HPCA-10 clones, and significant changes in the levels of these two proteins were not observed. Finally, positive control measurements with ß-actin antibodies showed that the levels ranged from 300 to 350 ng/mg protein in the tumor extracts, and there was no significant change in the levels of these proteins as a function of gene transfection or metastatic behavior of the tumors. Negative controls with secondary IgG antibodies produced basal levels of antigen binding (i.e., <0.5 ng/mg protein) in all the assays, and the values were corrected for this background level of nonspecific antibody binding.
Finally, duplicate studies with the three different HPCA-10a, 10b, 10c, and 10d tumor clones transfected with IL-10 or TGF-ß1 yielded results similar to that described for the HPCA-10a clone (data not shown).
Mouse Survival Studies
Mouse survival studies showed that mice implanted with HPCA-10a-TGF-ß1-expressing cells all died by 2–6 months (Fig. 12)
. The mice implanted with either HPCA-10a-IL-10 Mock or HPCA-10a-TGF-ß1 Mock cells all died by 3–6 months. In contrast, the mice implanted with HPCA-10a-IL-10 and HPCA-10a-IL-10 and TGF-ß1-transfected HPCA-10a cells had a >80% survival by 6 months (Fig. 12)
. Again, duplicate studies with the three different HPCA-10a, 10b, 10c, and 10d tumor clones transfected with IL-10, TGF-ß1, or both yielded results similar to that described for the HPCA-10a clone (data not shown).
|
|
DISCUSSION |
|---|
|
TopABSTRACTINTRODUCTIONMATERIALS AND METHODSRESULTSDISCUSSIONREFERENCES |
|---|
Immunolabeling and ELISAs further showed that the IL-10-transfected clones up-regulated TIMP-1 and down-regulated MMP-2 expression. In contrast, TGF-ß1 transfection had little effect on TIMP-1 but did up-regulate MMP-2. In the cotransfected cells, the MMP-2 levels were reduced significantly (compared with that observed in nontransfected and TGF-ß1-transfected tumor), presumably as a result of IL-10 effects. We have attempted to compare the relative levels of IL-10, TGF-ß1, TIMP-1, and MMP-2 expression with tumor growth and metastasis. The data showed that cells overexpressing IL-10 and TIMP-1 (with reduced MMP-2 levels) failed to grow large tumors or metastasize, whereas the converse was observed for tumors overexpressing TGF-ß1 and MMP-2. In accordance, the levels of factor VIII were very low in the IL-10-expressing tumors and elevated in the TGF-ß1-expressing tumors by 8–12 weeks, indicating that IL-10, TGF-ß1, TIMP-1, and MMP-2 expression might somehow indirectly influence angiogenesis. Studies of the metastatic lesions revealed that only a few tiny lesions developed from the HPCA-10-IL-10 clones or HPCA-10-IL-10 and TGF-ß1 clones, suggesting that IL-10 blockage of angiogenesis also blocked metastasis.
ELISAs indicated that the metastatic nodules uniformly expressed little or no IL-10 but did express relatively high levels of TGF-ß1 (i.e., in lung, liver, and peritoneum metastases from HPCA-10a-TGF-ß1 clones). ELISAs further showed that the metastases expressed little or no TIMP-1 but overexpressed MMP-2, indicating that metastasis was associated with the expression of these genes. Mouse survival studies further showed that mice implanted with HPCA-10a-IL-10 and HPCA-10a-IL-10 and TGF-ß1-transfected HPCA-10a cells had a >80% survival rate by 6 months, whereas mice injected orthotopically with HPCA-10a-TGF-ß1 clones died by 2–6 months. We conclude that IL-10 induction of TIMP-1 and inhibition of MMP-2 expression are inversely associated with metastatic ability and increased mouse survival. Conversely, TGF-ß1 induction of MMP-2 directly correlates with metastatic frequency and reduced mouse survival.
The results from the studies presented here were strongly supported by earlier in vitro studies from our laboratory, which showed that IL-10, IL-4, and to a lesser extent IL-6 stimulated the expression of TIMP-1 and decreased the levels of MMP-2 expression in primary prostate epithelial cell cultures (10) . Earlier studies by our laboratory also showed that IL-10 transfection also blocked tumor growth and metastasis by human prostate PC-3 ML tumor cells after orthotopic implantation in the prostate gland of SCID mice (18) . Measurements of tumor volume after 5, 8, and 12 weeks indicated that tumor volume and metastasis were negatively correlated with the amount of IL-10 production. Likewise, mouse survival rates increased to >80% in mice implanted with the IL-10-transfected PC-3 ML clones (18) . We suggest, therefore, that IL-10 expression and therapeutic approaches designed to enhance TIMP expression while reducing MMP-2 levels might be of therapeutic benefit in treating advanced prostate cancer.
A clear association between increased MMP-2 production and malignant aggressiveness has been observed in a number of different cancer types including prostate cancer (19) . Stetler-Stevenson and others (20, 21, 22, 23, 24, 25) have shown clearly that an increased expression of MMP-2 is normally observed in human malignant breast cancer (21 , 22) , colon adenocarcinomas (23 , 24) , and gastric cancer (24 , 25) . The investigators observed that the invasive ductal and lobular tumor cells expressed high levels of MMP-2, and increased collagenase expression was associated with the progression of tumors. In human prostate cancer, we have compared benign and malignant prostate tissue from transurethral resection of the prostate (n = 111, Ref. 26 ). In situ labeling clearly showed that the amounts of MMP-2 increased and TIMP-1 decreased with tumor progression to higher Gleason grades.
A number of laboratories have also investigated the effects of different cytokines on TIMP and MMP expression in a variety of cell lines. Studies examining the role of IL-6 on collagenase and TIMP-1 production in rat hepatocytes (27)
and human fibroblasts, synoviocytes, chondrocytes (28)
, and macrophages (29)
have indicated that IL-6 does not stimulate collagenase production but is a potent inducer of TIMP-1. In comparison, IL-4 and IFN-
were found to inhibit collagenase expression but not influence TIMP secretion (28)
. Lacraz et al. (28)
originally reported that IL-4 and IFN- suppressed matalloproteinase synthesis in macrophages without affecting TIMP levels. In a recent paper, Lacraz et al. (29)
compared the effects of IL-10, IL-4, IL-2, IL-6, and INF- on MMP-9, interstitial collagenase, and TIMP-1 synthesis in human macrophages and monocytes. They reported that IL-10 and IL-4 inhibited the production of MMP-9. IL-10 also stimulated TIMP-1 synthesis. Their data indicated that IL-10 controlled MMP-9 and TIMP-1 expression at a pretranslational phase, although steady-state and half-life mRNA studies were not carried out to assess whether IL-10 affected mRNA stability. Interestingly, they further found that IL-10 failed to influence MMP or TIMP production by human fibroblasts, suggesting that cell type-specific responses might be involved. Overall, these data are in strong agreement with the observations reported here. Others have further shown that IL-1, tumor necrosis factor-, and phorbol esters, which stimulate collagenase and stromelysin gene expression, also up-regulate TIMP expression. On the other hand, TGF-ß and retinoic acid, which repress MMP-1 and MMP-3 gene expression, are potent activators of TIMP expression (19)
. Clearly, these studies and our data strongly suggest that the regulation of MMPs and TIMPs are through independent mechanisms.
We believe that the orthotopic implantation of human tumor cells might be clinically relevant, because the natural regulation of gene expression and metastasis is no doubt strongly influenced by the host tissue stroma and microenvironment (9) . In and elegant study, Greene et al. (9) have shown that several genes expressed by highly metastatic PC-3M cells were up-regulated by implantation in the prostate gland and down-regulated by implantation s.c. in nude mice. Highly metastatic PC-3M cells expressed high levels of epidermal growth factor receptor, basic fibroblast growth factor, MMP-2, MMP-9, and multidrug resistance-1 mRNA transcripts after orthotopic implantation in the prostate gland compared with the low levels of these genes expressed by PC-3M cells injected ectopically (9) . More importantly, they reported a direct correlation between the orthotopic implantation, an elevated expression of these genes, and an increased frequency of metastasis (9) , indicating that the regulation of gene expression by the host tissue plays a major role in modulating metastasis. The data presented here strongly support these results and further validate the orthotopic model as ideal for analysis of genes regulating metastasis.
|
FOOTNOTES |
|---|
1 To whom requests for reprints should be addressed, at Department of Pathology and Laboratory Medicine, MCP-HUH University, MS 435, Broad and Vine Street, Philadelphia, PA 19102-1192. 
2 The abbreviations used are: IL-10, interleukin 10; TGF-ß1, transforming growth factor ß1; TIMP, tissue inhibitor of metalloproteinase; MMP, matrix metalloproteinase-2; HPCA, human prostate cancer adenocarcinoma; SCID, severe combined immunodeficiency; MTT, 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide.
Received 8/10/98; revised 11/19/98; accepted 12/ 8/98.
|
REFERENCES |
|---|
|
TopABSTRACTINTRODUCTIONMATERIALS AND METHODSRESULTSDISCUSSIONREFERENCES |
|---|
/ß CD4-8- subset. J. Exp. Med., 177: 1763-1771, 1993.This article has been cited by other articles:
|
|
 |
|
  F. Zhang, J. Lee, S. Lu, C. A. Pettaway, and Z. Dong Blockade of Transforming Growth Factor-{beta} Signaling Suppresses Progression of Androgen-Independent Human Prostate Cancer in Nude Mice Clin. Cancer Res., June 15, 2005; 11(12): 4512 - 4520. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. Panopoulou, C. Murphy, H. Rasmussen, E. Bagli, E. K. Rofstad, and T. Fotsis Activin A Suppresses Neuroblastoma Xenograft Tumor Growth via Antimitotic and Antiangiogenic Mechanisms Cancer Res., March 1, 2005; 65(5): 1877 - 1886. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Lu, J.-C. Soria, X. Tang, X.-C. Xu, L. Wang, L. Mao, R. Lotan, B. Kemp, B. N. Bekele, L. Feng, et al. Prognostic Factors in Resected Stage I Non-Small-Cell Lung Cancer: A Multivariate Analysis of Six Molecular Markers J. Clin. Oncol., November 15, 2004; 22(22): 4575 - 4583. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Lai, G. Z. Rassidakis, L. J. Medeiros, L. Ramdas, A. H. Goy, C. Cutler, Y. Fujio, K. Kunisada, H. M. Amin, and F. Gilles Signal Transducer and Activator of Transcription-3 Activation Contributes to High Tissue Inhibitor of Metalloproteinase-1 Expression in Anaplastic Lymphoma Kinase-Positive Anaplastic Large Cell Lymphoma Am. J. Pathol., June 1, 2004; 164(6): 2251 - 2258. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Asadullah, W. Sterry, and H. D. Volk Interleukin-10 Therapy--Review of a New Approach Pharmacol. Rev., June 1, 2003; 55(2): 241 - 269. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J.-C. Soria, C. Moon, B. L. Kemp, D. D. Liu, L. Feng, X. Tang, Y.-S. Chang, L. Mao, and F. R. Khuri Lack of Interleukin-10 Expression Could Predict Poor Outcome in Patients with Stage I Non-Small Cell Lung Cancer Clin. Cancer Res., May 1, 2003; 9(5): 1785 - 1791. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. A. Tuxhorn, G. E. Ayala, M. J. Smith, V. C. Smith, T. D. Dang, and D. R. Rowley Reactive Stroma in Human Prostate Cancer: Induction of Myofibroblast Phenotype and Extracellular Matrix Remodeling Clin. Cancer Res., September 1, 2002; 8(9): 2912 - 2923. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. Zhang, W. Lu, and Z. Dong Tumor-infiltrating Macrophages Are Involved in Suppressing Growth and Metastasis of Human Prostate Cancer Cells by INF-{beta} Gene Therapy in Nude Mice Clin. Cancer Res., September 1, 2002; 8(9): 2942 - 2951. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Suzuki, H. Nakazato, H. Matsui, M. Hasumi, Y. Shibata, K. Ito, Y. Fukabori, K. Kurokawa, and H. Yamanaka NK cell-mediated anti-tumor immune response to human prostate cancer cell, PC-3: immunogene therapy using a highly secretable form of interleukin-15 gene transfer J. Leukoc. Biol., April 1, 2001; 69(4): 531 - 537. [Abstract] [Full Text]
|
|
|
|
 |
|
 J. I. Izawa and C. P.N. Dinney The role of angiogenesis in prostate and other urologic cancers: a review Can. Med. Assoc. J., March 1, 2001; 164(5): 662 - 670. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J.-S. Silvestre, Z. Mallat, M. Duriez, R. Tamarat, M. F. Bureau, D. Scherman, N. Duverger, D. Branellec, A. Tedgui, and B. I. Levy Antiangiogenic Effect of Interleukin-10 in Ischemia-Induced Angiogenesis in Mice Hindlimb Circ. Res., September 15, 2000; 87(6): 448 - 452. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B.-J. Park, J.-I. Park, D.-S. Byun, J.-H. Park, and S.-G. Chi Mitogenic Conversion of Transforming Growth Factor-{beta}1 Effect by Oncogenic Ha-Ras-induced Activation of the Mitogen-activated Protein Kinase Signaling Pathway in Human Prostate Cancer Cancer Res., June 1, 2000; 60(11): 3031 - 3038. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J.-S. Silvestre, Z. Mallat, R. Tamarat, M. Duriez, A. Tedgui, and B. I. Levy Regulation of Matrix Metalloproteinase Activity in Ischemic Tissue by Interleukin-10: Role in Ischemia-Induced Angiogenesis Circ. Res., August 3, 2001; 89(3): 259 - 264. [Abstract] [Full Text] [PDF]
|
|
| |||||||||
, HPCA-10a Mock-IL-10 cells; —, HPCA-10a; and HPCA-10a cells transfected with IL-10 (
), TGF-ß1 (
), IL-10 plus TGF-ß1 (•), and HPCA-10a Mock-TGF-ß1 (—) cells.